Tokyo, Aug. 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062477) titled 'Implementation of Multidrug therapy for Preserved And mid-range EF in Acute Care' on Aug. 5.
Study Type:
Observational
Primary Sponsor:
Institute - Nihon University
Condition:
Condition - acute decompensated heart failure, worsening heart failure
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the implementation status (adoption rate of GDMT, especially SGLT2 inhibitor and finerenone) during hospitalization and at the time of discharge, as well as the clinical outcomes, safety, and continuity over the following one year.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
= 40%.
Key exclusion criteria - 1. Patients whose attending physician determines that so-called severe valvular disease was the primary cause of hospitalization (severe AS/AR/MR/MS, etc.).
2. Patients whose attending physician determines that so-called pneumoniae was the primary cause of hospitalization.
3. eGFR 5.0 mmol/L at screening (confirmed by repeat measurement if clinically indicated).
6. Pregnant or lactating female.
7. Patients whose investigator determines that these patients are inappropriate for study participation.
8. Cases in which the patient declined to participate in this study.
Target Size - 700
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2026 Year 04 Month 18 Day
Date of IRB - 2026 Year 05 Month 13 Day
Anticipated trial start date - 2026 Year 06 Month 01 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070533
Disclaimer: Curated by HT Syndication.
